A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin ...

Living in places with more air pollution raises the risk of eczema, a chronic condition that causes dry, itchy and inflamed ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

A dermatophyte known as Trichophyton mentagrophytes genotype VII (TMVII) has been identified as the cause of an emerging ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

According to a study published in Biomaterials Advances, scientists at the University of Copenhagen have developed a patch ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...